Overview

Update
IPO / Stock
Went Public on Nov 16, 2007 / EBR:ABLX
Total Equity Funding
$84.9M in 3 Rounds from 8 Investors
Headquarters:
Zwijnaarde
Description:
Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.
Founders:
Categories:
Pharmaceutical, Biopharma, Biotechnology
Website:
http://www.ablynx.com
Social:

Company Details

Update

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Funding Rounds (7) - $268.84M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2016$82.8M / Post Ipo Equity0
Aug, 2014€2.1M / Grant0
Jun, 2014€41.7M / Post Ipo Equity0
Feb, 2013€31.5M / Post Ipo Equity0
Aug, 2006$50M / Series C8
Apr, 2004$30M / Series B6
Sep, 2002€5M / Venture3

Current Team (8)

Update

Offices/Locations (1)

Update
  • Office

    Technologiepark 21

    Zwijnaarde, 9052

    BEL

Past Team (8)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos